Gossamer Bio, Inc.

NASDAQ:GOSS

Biotechnology

Healthcare
$11.43 +3.24%

+$0.01 today

Market cap
$69.91M
Beta
2.04
P/E (TTM)
-0.2
EPS (TTM)
-$0.77
52W Low $0.11High $3.87

Volume 0.24M

Average 19.76M

GOSS Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Gossamer Bio, Inc.NASDAQ: GOSS

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit growth accelerates

Q1 FY2026 gross profit of $16.72M rose 69.1% year over year, ahead of the -55.6% change in trailing-twelve-month gross profit. Sequentially, it rose 21.2% from the prior quarter.

Context

  • Gross profit amounted to 97.9% of revenue in FY2025, down 2.1 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +69.1% holds above the trailing-twelve-month pace of -55.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$16.72M+21.2% QoQ
Last fiscal yearDec 2025
$47.47M-58.6% YoY
LTMMar 2026
$55.3M-55.6% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+69.1%——
1 year-58.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
47.47M USD
Year-over-year change
-58.6%

Gross Profit vs competitors

How GOSS compares with its peers on the latest reported figures

  • GOSS's LTM Mar 2026 gross profit of $55.3M is the 4th highest of the 9 companies compared; the peer median is $13.54M.
  • Its year-over-year change of -55.6% is the 4th highest of 6, against a peer median of +53.8%.
  • Gross profit amounts to 99.6% of revenue for GOSS, versus a peer median of 69.4%.
GOSS Competitors Peer median
Gross Profit for GOSS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$279.95M +53.8%+32.3%93.4%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$106.66M ——92.0%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$69M +1276.4%—99.1%
GOSSGossamer Bio, Inc.LTM Mar 2026$55.3M -55.6%—99.6%
PRTAProthena Corporation plcLTM Mar 2026$27.14M -80.3%-51.9%46.8%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$55K ———
RGNXREGENXBIO Inc.LTM Mar 2026-$120K -100.1%+37.2%0.1%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026-$306K ———
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$10.98M +90.3%—12.4%
Peer median (excluding GOSS) $13.54M+53.8%+32.3%69.4%

Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000114.7M48.47M
Cost of Revenue00001M
Gross Profit000114.7M47.47M
Gross Margin———100.0%97.9%
Research & Development170.27M170.92M135.3M138.49M174.09M
Selling, General & Admin45.78M47.61M38.46M36.13M37.63M
Operating Expenses216.12M218.59M183.76M174.62M210.72M
Depreciation & Amortization5.17M4.43M4.39M4.15M1M
EBITDA(209.4M)(211.07M)(161.92M)(39.97M)(158.47M)
EBITDA Margin———-34.8%-326.9%
Operating Income(216.12M)(218.59M)(183.76M)(59.92M)(163.25M)
Operating Margin———-52.2%-336.8%
Interest Income761K1.58M2M1.78M1.97M
Interest Expense19.44M13.88M13.51M11.52M10.99M
Other Income / Expenses(17.88M)(10.79M)3.94M4.28M(7.21M)
Income Before Tax(234M)(229.38M)(179.82M)(55.64M)(170.46M)
Pre-Tax Margin———-48.5%-351.7%
Income Tax Expense000893K(88K)
Net Income(234M)(229.38M)(179.82M)(56.53M)(170.37M)
Net Margin———-49.3%-351.5%
EPS (Basic)(3.33)(2.84)(0.80)(0.25)(0.75)
EPS (Diluted)(3.33)(2.84)(1.18)(0.25)(0.75)
Weighted Avg Shares74.84M84.57M225.57M226.23M228.52M
Weighted Avg Shares (Diluted)74.84M84.57M225.57M226.23M228.52M

Gossamer Bio, Inc.

NASDAQ:GOSS

Intrinsic Alpha fair value

Locked

Current Price

$11.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.